TNFRSF9 and cancer: While 4-1BB is a cancer immunotherapy target used in CAR-T cell and monoclonal antibodies modalities, an early study showed that agonistic 4-1BB antibody could trigger immune-suppression and alleviate an autoimmune disease in the eye known as experimental autoimmune uveoretinitis (EAV) [43].